Spark Investment Management LLC Buys Shares of 60,400 Aptinyx Inc (APTX)
Spark Investment Management LLC bought a new stake in shares of Aptinyx Inc (NASDAQ:APTX) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 60,400 shares of the company’s stock, valued at approximately $244,000.
Several other institutional investors have also added to or reduced their stakes in the company. Gabelli Funds LLC bought a new stake in Aptinyx in the first quarter valued at about $44,000. Geode Capital Management LLC increased its holdings in Aptinyx by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 107,464 shares of the company’s stock valued at $1,777,000 after purchasing an additional 17,914 shares during the last quarter. Millennium Management LLC bought a new stake in Aptinyx in the fourth quarter valued at about $266,000. Metropolitan Life Insurance Co. NY increased its holdings in Aptinyx by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the last quarter. Finally, Partner Fund Management L.P. increased its holdings in Aptinyx by 5.6% in the fourth quarter. Partner Fund Management L.P. now owns 1,852,132 shares of the company’s stock valued at $30,634,000 after purchasing an additional 97,453 shares during the last quarter. Institutional investors own 62.69% of the company’s stock.
NASDAQ:APTX traded up $0.07 on Friday, reaching $3.40. The company’s stock had a trading volume of 90 shares, compared to its average volume of 401,245. Aptinyx Inc has a 1-year low of $3.27 and a 1-year high of $32.25. The stock has a market cap of $111.76 million and a price-to-earnings ratio of -1.28.
A number of research firms have issued reports on APTX. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. BMO Capital Markets reissued an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Finally, Zacks Investment Research cut Aptinyx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.95.
In other news, Director Henry O. Gosebruch acquired 100,000 shares of Aptinyx stock in a transaction dated Wednesday, May 8th. The stock was bought at an average cost of $3.86 per share, with a total value of $386,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.47% of the stock is owned by corporate insiders.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Story: Total Return
Want to see what other hedge funds are holding APTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptinyx Inc (NASDAQ:APTX).
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.